D.A. Davidson & CO. reduced its stake in shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) by 3.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 210,373 shares of the biopharmaceutical company’s stock after selling 8,645 shares during the quarter. D.A. Davidson & CO. owned 0.18% of Juno Therapeutics worth $9,436,000 at the end of the most recent quarter.
Several other large investors also recently made changes to their positions in JUNO. Vanguard Group Inc. grew its position in Juno Therapeutics by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after purchasing an additional 131,864 shares during the period. BlackRock Inc. grew its position in Juno Therapeutics by 2.6% in the 2nd quarter. BlackRock Inc. now owns 4,294,296 shares of the biopharmaceutical company’s stock worth $128,357,000 after purchasing an additional 110,503 shares during the period. State Street Corp grew its position in shares of Juno Therapeutics by 7.4% during the 2nd quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock valued at $96,742,000 after acquiring an additional 222,754 shares during the period. Capital World Investors grew its position in shares of Juno Therapeutics by 13.8% during the 2nd quarter. Capital World Investors now owns 2,425,000 shares of the biopharmaceutical company’s stock valued at $72,483,000 after acquiring an additional 295,000 shares during the period. Finally, Redmile Group LLC bought a new stake in shares of Juno Therapeutics during the 2nd quarter valued at $66,344,000. 70.37% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 price objective (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Maxim Group reissued a “buy” rating and set a $56.00 price objective on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Goldman Sachs Group restated a “neutral” rating and set a $44.00 target price on shares of Juno Therapeutics in a research note on Friday, October 6th. Citigroup restated a “buy” rating and set a $59.00 target price on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Finally, Wedbush upgraded shares of Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 target price on the stock in a research note on Tuesday, August 29th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $45.48.
In other Juno Therapeutics news, General Counsel Bernard J. Cassidy sold 28,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $44.92, for a total value of $1,257,760.00. Following the completion of the transaction, the general counsel now owns 55,970 shares of the company’s stock, valued at $2,514,172.40. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total transaction of $366,296.70. Following the completion of the transaction, the executive vice president now directly owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The disclosure for this sale can be found here. Insiders have sold 54,801 shares of company stock valued at $2,527,741 in the last three months. 15.08% of the stock is currently owned by corporate insiders.
Juno Therapeutics, Inc. (NASDAQ:JUNO) opened at $56.73 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $63.45.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter in the prior year, the company earned ($0.57) EPS. The company’s revenue was up 115.4% compared to the same quarter last year. equities research analysts expect that Juno Therapeutics, Inc. will post -4.02 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Juno Therapeutics, Inc. (JUNO) Holdings Decreased by D.A. Davidson & CO.” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.thelincolnianonline.com/2017/12/08/juno-therapeutics-inc-juno-shares-sold-by-d-a-davidson-co-updated-updated.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.